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Abstract
Genomic regions of homozygosity (ROH), detectable in outbred populations, have
been implicated as determinants of inherited risk. To examine whether ROH is asso-
ciated with risk of multiple myeloma (MM), we performed whole-genome homozy-
gosity analysis using single-nucleotide polymorphism genotype data from 2,282 MM
cases and 5,197 controls, with replication in an additional 878 MM cases and 7,083
controls. Globally, the distribution of ROH between cases and controls was not sig-
niﬁcantly diﬀerent. However, one ROH at chromosome 9q21, harboring the B-cell
transcription factor gene KLF9, showed evidence of a consistent association and may
therefore warrant further investigation as a candidate risk factor for MM. Overall, our
analysis provides little support for a homozygosity signature being a signiﬁcant factor
in MM risk.
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1 INTRODUCTION
Multiple myeloma (MM) is a malignancy of plasma cells
that has a signiﬁcant heritable component as evidenced by
the two- to fourfold increased risk shown in relatives of MM
patients (Altieri, Chen, Bermejo, Castro, & Hemminki, 2006;
Palumbo & Anderson, 2011).
Recent genome-wide association studies (GWAS) have
provided the ﬁrst risk alleles for MM identifying common
(minor allele frequency [MAF] >5%) single-nucleotide poly-
morphisms (SNPs) at 17 independent loci (Broderick et al.,
2011; Chubb et al., 2013; Mitchell et al., 2016; Swaminathan
et al., 2015; Went & Sud, 2018). Although these SNPs indi-
vidually have modest eﬀects on risk (odds ratio [OR] typically
<1.5), their identiﬁcation has yielded novel insights into MM
biology, implicating disruption of B-cell biology and chro-
matin remodeling pathways in development of the disease
(Mitchell et al., 2016).
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Whereas much of the heritable risk of MM is likely to be
enshrined in such polygenic susceptibility, statistical model-
ing indicates that a signiﬁcant fraction of the familial risk
will be unexplained (Mitchell et al., 2015). A number of
possible explanations for this missing heritability have been
proposed including rare and recessive alleles (Manolio et al.,
2009; Mitchell et al., 2015). Common regions of homozygos-
ity (ROH), the result of autozygosity (i.e., occurrence of two
alleles at the same locus originating from a common ances-
tor as a consequence of nonrandom mating), have been docu-
mented to be detectable at high frequency in outbred popula-
tions as a consequence of selective pressure (Ku, Naidoo, Teo,
& Pawitan, 2011; Lencz et al., 2007). Searching for ROH on
a genome-wide basis therefore aﬀords a strategy for discov-
ery of recessively acting disease genes and has been exploited
in studies of rheumatoid arthritis (Yang, Chang, Liang,
Lin, & Wang, 2012), Alzheimer's (Ghani et al., 2015), and
early-onset Parkinson's disease (Simon-Sanchez et al., 2012).
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Findings from these studies support the hypothesis that reces-
sive, disease-predisposing loci not readily detected using a
conventional GWAS approach exist (Yang et al., 2012). A pos-
sible reason for this apparent failure of conventional GWAS
is that the relative risks per locus are too modest and/or that
the disease-associated variants are not in strong linkage dise-
quilibrium (LD) with the tag SNPs.
Although GWAS may therefore have limited ability to
identify recessive disease alleles through SNP analyses, such
data sets can potentially be exploited in the search for reces-
sively acting disease loci through whole-genome homozy-
gosity analysis (WGHA). To explore this prospect in MM,
we implemented WGHA using SNP genotype data from two
GWAS data sets totaling 3,160 cases and 12,280 controls.
2 METHODS
2.1 Discovery GWAS
For the discovery analysis, we analyzed genotype data from
a previously described (Broderick et al., 2011) GWAS, which
comprised 2,282 MM cases ascertained through the UK Med-
ical Research Council (MRC) Myeloma-IX trial (Morgan
et al., 2010). Genotype data on 5,197 individuals from the UK
Welcome Trust Case-Control Consortium 2 (WTCCC2) study
of individuals from the 1958 British Birth Cohort (58C) (also
known as the National Child Development Study) and the
UK Blood Service collections served as controls. Cases were
genotyped using Illumina Human OmniExpress-12 (Version
1.0 array; Illumina, San Diego, CA) and controls using Illu-
mina Human 1-2M-Duo Custom (Version 1 array chips).
2.2 Replication GWAS
For replication, we utilized genotype data generated on an
additional series 878 MM cases ascertained through the UK
MRC Myeloma-IX and Myeloma-XI trials. Controls con-
sisted of (1) 2,976 cancer-free men recruited by the PRAC-
TICAL Consortium—the UK Genetic Prostate Cancer Study
(age <65 years), a study conducted through the Royal Mars-
den NHS Foundation Trust and SEARCH (Study of Epidemi-
ology & Risk Factors in Cancer Heredity), recruited general
practices in East Anglia (2003–2009), and (2) 4,446 cancer-
free women across the United Kingdom, recruited via the
Breast Cancer Association Consortium. Both cases and con-
trols were genotyped using Illumina OncoArray.
2.3 Ethics
Collection of patient samples and associated medical infor-
mation was undertaken with ethical review board approval,
speciﬁcally, for theMyeloma-IX trial, by theMRCLeukaemia
Data Monitoring and Ethics Committee (MREC 02/8/95,
ISRCTN68454111), and for the Myeloma-XI trial, by the
Oxfordshire Research Ethics Committee (MREC 17/09/09,
ISRCTN49407852). The diagnosis of MM (ICD-10 C90.0)
was established in accordance with World Health Organiza-
tion guidelines.
2.4 Quality control
Both GWAS have previously been subject to stringent quality
control (Broderick et al., 2011; Chubb et al., 2013; Mitchell
et al., 2016; Swaminathan et al., 2015). Brieﬂy, samples with a
low SNP call rate (<95%) were excluded, as were SNPs where
<95% of DNA samples generated a genotype at the locus.
We excluded individuals of non-European ancestry (using
the HapMap Version 2 CEU, JPT/CHB, and YRI popula-
tions as reference). For apparent ﬁrst-degree relative pairs, we
excluded the control from a case-control pair; otherwise, we
excluded the individual with the lower call rate. SNPs with
a MAF <1% or displaying signiﬁcant deviation from Hardy–
Weinberg equilibrium (p < 10−5) were excluded. Genotypes
were imputed to >10 million SNPs using IMPUTE2 (Version
2.3) (Howie, Donnelly, & Marchini, 2009) software in con-
junctionwith amerged reference panel consisting of data from
the 1000 Genomes Project (Abecasis et al., 2010) (phase 1
integrated release March 3, 2012) and UK10K, retaining only
alleles with an INFO score of >0.8.
2.5 Identification of ROH
PLINK (Version 1.9) (Purcell et al., 2007) was used to search
for ROH with a speciﬁed length, inputted in the homozyg-
SNP parameter, of 73 for the discovery data set and 100
for the replication data set. This resulted in an ROH length
that was more than an order of magnitude larger than the
mean haploblock size in the human genome without being so
large as to be very rare. The likelihood of observing, in the
case of the discovery data set, 73 consecutive chance events
can be calculated on the basis that mean heterozygosity in
the controls was 35%. Given 408,422 SNPs and 7,478 indi-
viduals, a minimum length of 57 would be required to pro-
duce <5% randomly generated ROH across all subjects (i.e.,
(1–0.35)57 × 408,422× 7,478= 0.047). A consequence of LD
is that the SNP genotypes are not always independent. Anal-
ysis based on PLINK's pairwise LD SNP pruning function
revealed 311,773 separable tag groups, representing a 24%
reduction of information compared to the original number of
SNPs. Thus, ROH of length 73 were used to approximate the
degrees of freedom of 57 independent SNP calls.
Following this, an ROHof≥73 SNPs in length were pruned
to only those that occurred in more than 10 individuals.
To ensure that a minimum length and number of SNPs in
each ROH was maintained, each individual's SNP data were
recoded as one if the SNP was in an ROH for that individual
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F IGURE 1 Cumulative distributions of regions of homozygosity (ROH) in cases and controls of (a) discovery, and (b) replication data sets.
Each data point represents the cumulative fraction of the samples with the corresponding minimum run of homozygosity
TABLE 1 Comparison of regions of homozygosity (ROH) distribution and length in cases versus controls for discovery and replication data
sets
Discovery Replication
Cases Controls p-Value Cases Controls p-Value
Mean number ROH 15.44 15.7 0.016 21.51 21.69 0.22
Mean total length kb (SD) 232 (63) 230 (63) 0.15 355 (72) 360 (75) 0.12
and zero otherwise. Each SNP present in fewer than 10 indi-
viduals were then recoded to zero before any ROH that were
subsequently less than the required number of SNPs in length
were removed. This resulted in a list of “common” ROH with
a minimum of 73 consecutive ROH calls across 10 or more
samples. To investigate association of ROH at a locus, we
considered those ROHs with p-value <0.01 in the discovery
data set.
2.6 Statistics and bioinformatics
We detected ROH using PLINK (Version 1.9), which views
a sliding window of SNPs across the genome. We exam-
ined broad-sense ROH, which considers a homozygosity-rich
region containing a small proportion of heterozygotes, the
result of genotyping errors, artiﬁcial heterozygosity, or muta-
tions. Speciﬁcally, our analysis allowed for 2% heterozygotes
in each window to prevent an underestimation of the number
and size of ROH. The remaining options were set to default
values (including allowing ﬁve missing calls per window),
with the exception of the homozyg-SNP parameter that was
calculated for each data set according to the aforementioned
method for deﬁning the ROH length. Statistical analyses were
performed using R (Version 3.4) and data was formatted using
Perl code. A χ2 test was used to compare the distribution of
categorical variables between cases and controls. To compare
the diﬀerence in average number of ROH between cases and
controls, we used a Student's t-test. Meta-analyses were per-
formed in R (Version 3.3.1) using the ﬁxed-eﬀects inverse-
variance method.
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To provide evidence of positive selection at each locus,
we obtained iHS, D, and Fst metrics from dbPSHP (Li et al.,
2014). iHS measures the extent of LD surrounding a locus,
with an extreme absolute value being indicative of a posi-
tively selected allele (Voight, Kudaravalli, Wen, & Pritchard,
2006). Tajima's D metric infers selection by quantifying the
diﬀerence between number of segregating sites and average
number of nucleotide diﬀerences, with a large diﬀerence
being indicative of selection (Tajima, 1989). Fst assesses the
proportion of genetic diversity as a result of allele frequency
diﬀerences within a sample population versus the entire pop-
ulation (Holsinger & Weir, 2009).
3 RESULTS
After imposing stringent quality control to GWAS data sets,
the discovery GWAS provided genotype data on 2,282 cases
and 5,197 controls, and the replication GWAS genotype data
on 878 cases and 7,083 controls (Supplementary Tables 1
and 2).
Using PLINK, we found a total of 393 ROH in the
discovery data set (Supplementary Table 3, Supplementary
Figure 1). The mean number of ROH was lower in cases
than in controls (p = 0.016), although the mean total length
of ROH present was not signiﬁcantly diﬀerent (cases 232
Mb, controls 230 Mb; p = 0.15; Table 1). The cumula-
tive length of ROH in cases and controls was computed
to examine the cumulative distribution in each (Figure 1).
ROH encompassing the centromere were seen on chromo-
somes 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 16, 17, 18, 19,
and 20, including a previously described ROH (Lencz et al.,
2007) that bounded the centromere on chromosome 8 and
hence served as a control. The longest ROH (44.2 Mb)
was the one spanning the centromeric region of chromo-
some 1. Six regions showed a diﬀerence in frequency between
cases and controls at a p < 0.01 level of signiﬁcance
(Table 2).
We sought validation of these ﬁndings in the replication
GWAS data set. Overall, 362 ROH were found in the replica-
tion data set (Supplementary Table 4). As was the case with
the discoveryGWAS data set, ROH that encompassed the cen-
tromere were identiﬁed on chromosomes 1, 2, 3, 4, 5, 6, 7,
8, 10, 11, 12, 16, 17, 18, 19, and 20, with the longest ROH
(46.4 Mb) spanning the centromere of chromosome 1. The
average length of ROH in the replication data set (5.65 Mb),
was comparable with that found in the discovery (5.07 Mb)
series. In contrast to the discovery series, the average num-
ber of ROH in the replication data set was not signiﬁcantly
diﬀerent between cases and controls (Table 1). Furthermore,
the mean total length of ROH was not signiﬁcantly diﬀer-
ent (cases: 355 Mb, controls: 360 Mb; p = 0.12; Table 1).
The cumulative distribution provided a demonstration of the T
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F IGURE 2 Plot of overlapping region of discovery (navy) and replication regions of homozygosity (light blue) on (a) chromosome 9, and
(b) chromosome 10. Coordinates are from the National Center for Biotechnology Information Build 37 human genome [Colour ﬁgure can be viewed
at wileyonlinelibrary.com]
comparability in distribution of ROH between cases and con-
trols (Figure 1).
Of the six candidate ROH linked to MM risk in the discov-
ery GWAS, two ROH located at 9q21 and 10q22 showed a
consistent direction of eﬀect, with 9q21 having a comparable
frequency (Table 2). The combined p-values for the consen-
sus ROH regions at 9q21 and 10q22 (Figure 2), were 0.01 and
0.18, respectively (Table 2). Although the 9q21 association is
not signiﬁcant after adjusting formultiple testing, such correc-
tion can result in a type II error. Support for positive selection
of this region is provided by the associated high D and iHS
metrics (Table 2). Intriguingly, the consensus region for the
ROH at 9q21, contains the gene encoding the transcription
factor KLF9. Decreased levels of KLF9 have been implicated
in a hyperproliferative B-cell response and defective Ig pro-
duction (Good & Tangye, 2007; Savignac et al., 2010) and
a predictive marker of sensitivity to bortezomib treatment in
MM (Mannava et al., 2012; Ri, 2016).
4 DISCUSSION
Recent studies have suggested that analysis of genomic ROH
may provide evidence of cancer risk (Assie, Laframboise,
Platzer, & Eng, 2008; Thomsen et al., 2016a, 2016b; Wang
et al., 2013). Speciﬁcally, that interrogation of locus-speciﬁc
ROH can provide a strategy to identify recessive disease-
causing variants. Generally, the strategy has been applied to
populations characterized by an increased degree of inbreed-
ing (Feldman, Lee, & Seligman, 1976), although there is evi-
dence that the success in such populations may be attributed
to confounding factors (Abdellaoui et al., 2013, 2015;
Ceballos, Joshi, Clark, Ramsay, & Wilson, 2018; Mitchell
et al., 2016). More recently, the strategy has been applied in
outbred populations; however, few of the reported analyses
have sought replication of study ﬁndings. It is notable that in a
recent WGHA of schizophrenia risk, attempts to validate pre-
vious ﬁndings have failed despite a well-powered replication
analysis (Mitchell et al., 2016).
Here, we have sought to mitigate against confounding fac-
tors or the winner's curse (Palmer & Pe'er, 2017) by investi-
gating the homozygosity signature of SNP genotype data ﬁrst
in a discovery and then in an independent replication data set,
totaling 3,160MMcases and 12,280 population-matched con-
trols. A further strength of our analysis is the stringent quality
control applied to each of the data sets; notably, both had no
demonstrable evidence of population stratiﬁcation. Finally, to
search formeaningful ROH and avoid inﬂation because of cor-
related SNPs, we adjusted computed ROH length to account
for the fraction of SNPs that were in tagged regions.
Our discovery WGHA and replication provided no evi-
dence of an association between global or individual ROH
and MM risk. While not statistically signiﬁcant after
correction for multiple testing, an ROH at 9q21 showed a
consistent direction of eﬀect. The consensus region at 9p21
implicates the transcription factor KLF9, which, when given
6 WENT ET AL.
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a plausible biological role in MM pathogenesis, may warrant
further investigation.
In conclusion, our analysis provides little support for a
homozygosity signature being a signiﬁcant factor in MM risk.
However, we cannot exclude the possibility of recessive alle-
les inﬂuencing MM risk.
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